Novo Nordisk strengthens executive team with new appointments

Novo Nordisk strengthens executive team with new appointments

(IN BRIEF) Novo Nordisk has announced changes to its executive management team. Monique Carter, the current EVP of Global People & Organisation, is leaving the company to pursue an external opportunity and will be succeeded by Tania Sabroe, who has been promoted to EVP from her previous role as SVP in the same department. Additionally, Dave Moore has been promoted to EVP of Corporate Development and will also join the Executive Management team. These changes are effective immediately.

(PRESS RELEASE) BAGSVÆRD, 7-Mar-2023 — /EuropaWire/ — Novo Nordisk A/S (CPH: NOVO-B), a Danish multinational pharmaceutical company, announces a few executive management changes effective immediately. Monique Carter, the current Executive Vice President (EVP) of Global People & Organisation, will be stepping down from her role to pursue an external opportunity that will allow her to be closer to her family in the UK. Carter joined the company in 2018 as Senior Vice President (SVP) for People & Organisation, and in 2019, she was promoted to EVP.

Taking over the role of EVP, Global People & Organisation is Tania Sabroe, who has been promoted from her previous role as SVP in the same department. Sabroe has been with Novo Nordisk since August 2007 and has held various roles of increasing importance and complexity in the fields of people and organisation, sustainability, and communication. She is a Danish national currently based in Switzerland, where she worked in International Operations from 2013 to 2021.

In addition, Dave Moore has been promoted to EVP of Corporate Development and will also join the Executive Management team. Moore joined Novo Nordisk in September 2022 as SVP for Corporate Development with responsibility for strategy and business development. Before joining the company, Moore held various leadership roles in the pharmaceutical industry in the US, working in international large pharma companies, biotech companies, and private equity. From 2017 to 2019, Moore was SVP for commercial operations in Novo Nordisk in the US. He is a US national and is based in the US.

Novo Nordisk wishes Monique Carter all the best in her future endeavors and welcomes Tania Sabroe and Dave Moore to their new roles in the Executive Management team.

With these changes, Executive Management will have the following members as of 7 March 2023:

• Lars Fruergaard Jørgensen, president and CEO
• Maziar Mike Doustdar, EVP, International Operations*
• Ludovic Helfgott, EVP, Rare disease*
• Karsten Munk Knudsen, EVP, chief financial officer
• Doug Langa, EVP, North America Operations*
• Martin Holst Lange, EVP, Development
• Dave Moore, EVP, Corporate Development*
• Tania Sabroe, EVP, People & Organisation*
• Marcus Schindler, EVP, chief scientific officer, Research & Early Development
• Camilla Sylvest, EVP, Commercial Strategy and Corporate Affairs
• Henrik Wulff, EVP, Product Supply, Quality & IT

* Not registered as an executive with the Danish Business Authority.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Contact for further information